What one share of Caribou Biosciences holds
We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
Caribou Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.10 |
|---|---|
| Profit | −$1.08 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | −$1.00 |
| Cash and investments | $0.25 |
| Book value | $0.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.69 | −$2.80 | $0.11 | −$3.93 | — | $0.89 |
| 2020 | $1.45 | −$4.01 | $0.04 | −$3.92 | — | −$2.41 |
| 2021 | $0.30 | −$2.11 | $0.07 | −$1.09 | — | $6.44 |
| 2022 | $0.23 | −$1.64 | $0.11 | −$1.60 | — | $4.93 |
| 2023 | $0.47 | −$1.38 | $0.16 | −$1.42 | — | $4.17 |
| 2024 | $0.11 | −$1.65 | $0.05 | −$1.58 | — | $2.74 |
| 2025 | $0.12 | −$1.59 | $0.01 | −$1.20 | — | $1.28 |
Common questions about Caribou Biosciences
How much does one share of Caribou Biosciences earn?
Over the last 12 months, Caribou Biosciences lost $1.08 for each share on $0.10 of sales.
Does Caribou Biosciences pay a dividend?
Caribou Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Caribou Biosciences’s book value per share?
Caribou Biosciences’s book value is $0.93 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Caribou Biosciences have?
Each share of Caribou Biosciences has $0.25 of cash and investments, as of June 30, 2026.
What is Caribou Biosciences’s free cash flow per share?
−$1.00 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Caribou Biosciences bought back shares?
Caribou Biosciences’s share count rose about 1015% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.